#Miami #Israel #biotech funding #Greenberg Traurig #Entera Bio

Greenberg Traurig Facilitates Record-Breaking Financial Move for Entera Bio

In a remarkable milestone for the Israeli biotech landscape, Greenberg Traurig, P.A. has successfully advised Entera Bio Ltd. (NASDAQ: ENTX) in completing an impressive $275 million private placement financing. This substantial infusion is recognized as the largest publicly disclosed Israeli biotech PIPE (Private Investment in Public Equity) transaction to date. Moreover, it stands as the ninth-largest PIPE across all sectors in Israel, as cataloged by Arx Capital Markets, which manages investor relations for Entera Bio.

The chief aim of this significant funding is to bolster Entera Bio's capabilities in developing EB613, an innovative oral peptide aimed at treating osteoporosis. This financing will effectively extend the company’s operational runway through to 2030, enabling the firm not just to continue its research but also to adequately support its Phase 3 registrational studies. EB613 represents a groundbreaking step forward as it stands to be the first oral tablet comprising PTH (1-34) peptide developed specifically for osteoporosis treatment.

The transaction was primarily overseen by a dedicated team from Greenberg Traurig comprising Drew M. Altman, co-chair of the Miami Corporate Practice, along with corporate shareholder Sami B. Ghneim. The team also included corporate associate Angel A. Marcial and managing shareholder of the Tel Aviv office, Joey T. Shabot. Their collective expertise was instrumental in navigating the complexities of this significant financing.

Significance of the Financing

The ramifications of this funding extend far beyond Entera Bio itself, marking a notable trend in the Israeli biotech sector. The substantial investment reflects growing confidence among investors in the potential of oral peptide therapies, a market that holds significant promise due to advancements in drug delivery technologies.

Entera Bio has positioned itself as a leading player in this field, demonstrating a commitment to innovation that resonates with the sector's evolving landscape. The firm's focus on developing oral therapies could revolutionize treatment methodologies for conditions like osteoporosis, a disease that affects millions across the globe, particularly the aging population.

Greenberg Traurig's Role in the Sector

Greenberg Traurig has long been at the forefront of providing legal services to various industries, with a compelling focus on the ever-expanding biotech and pharmaceutical sectors. With a network of over 3,200 attorneys across 51 locations, the firm is equipped to offer comprehensive support, helping clients like Entera Bio navigate regulatory challenges, secure funding, and achieve their strategic goals.

In its role, Greenberg Traurig emphasizes innovative and strategic legal services tailored to meet the unique needs of biotech firms. Recognized as one of the Best Recommended Law Firms by the General Counsel in 2025, the firm continues to build a legacy of successful transactions and proactive legal support.

As the industry matures, partnerships such as that between Greenberg Traurig and Entera Bio are critical. The success of the $275 million funding not only highlights the potential of oral therapies but also serves as a catalyst for future investments in Israel's biotech landscape, potentially inspiring other ventures to follow suit.

Conclusion

The partnership between Greenberg Traurig and Entera Bio represents a paradigm shift within the biotech investment sphere. With substantial funding in place, Entera Bio is positioned to make significant advancements in osteoporosis treatment, showcasing the increasing synergy between innovative health solutions and financial backing. As this sector continues to evolve, stakeholders will be keenly observing how these developments unfold and what new avenues of opportunity may arise from this landmark financing endeavor.

This historic transaction underscores a vibrant future for biotechnology in Israel, with Greenberg Traurig playing an essential role in this unfolding narrative. The legal firm’s expertise and Entera Bio’s innovative approach promise to drive forward the advancements critical to tackling pressing health challenges worldwide.